Close menu




March 13th, 2023 | 13:10 CET

Bank quake? Our assessment! SVB Financial, Credit Suisse, Aspermont

  • Digitization
  • Technology
  • Banking
  • Investments
  • SVB
  • CreditSuisse
  • Aspermont
Photo credits: pixabay.com

If you were unfamiliar with the US bank SVB until last Thursday, at least you did not have much of an education gap. The bank was forced to sell bonds under pressure and made losses in the billions. The share price collapsed, and a capital increase failed. We look at the latest status around SVB and what lessons investors can learn from the situation.

time to read: 4 minutes | Author: Nico Popp
ISIN: SVB FINL GROUP DL-_001 | US78486Q1013 , CREDIT SUISSE GP AG ADR 1 | US2254011081 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    SVB Financial: Authorities react, but what does SVB UK do?

    On Friday morning US time, a hastily sought capital increase to provide SVB Financial with new funds failed. For days, the Silicon Valley bank, which primarily finances growth companies, is believed to have been exploring new options for rescue. A takeover by another financial institution is also open to debate. SVB is one of the twenty largest financial institutions in the US, according to industry experts. Partly because of this, the bank's troubles infected the markets last week, dragging down bank stocks in particular. Meanwhile, authorities in the US seized the bank's deposits and wound up the institution. Investors will get their money back next week. At the same time, observers are eyeing the British offshoot SVB UK. Authorities in the UK also announced over the weekend that they would take action to prevent contagion effects.

    However, it is unlikely that the current situation is the beginning of a new financial crisis that began in 2007 with the collapse of hedge funds and culminated in the collapse of Lehman Brothers and numerous billion-dollar rescues of banks around the globe. First, SVB operates as a partner to growth companies in a niche particularly burdened by rising interest rates. Second, thanks to stricter regulatory requirements, banks are much more solidly positioned today than in 2007. In addition, managing the interest rate risks of bond portfolios is part of everyday life for banks. In the case of SVB, the interplay of several events likely caused the distress.

    Credit Suisse: Problem child now in focus

    The fact that rising interest rates can also cause problems for banks was already demonstrated last year by the example of Credit Suisse. The Swiss bank posted losses in the billions. Weak ratings are putting a strain on the investment banking business, which is doing well, and are scaring off wealthy clients who traditionally like investing in Switzerland. The starting point for Credit Suisse's misery was business with the supply chain financier Greensill and the hedge fund Archegos, which has since slid into bankruptcy. The Swiss bet too big on both collaborations and ultimately lost - which does not cast a positive light on Credit Suisse's risk management. At the end of last week, Credit Suisse also postponed its financial results - the US securities regulator pointed out unresolved issues with its accounting to the bankers. It is no wonder that investors are putting one and one together in the mirror of SVB's difficulties in the US: the share has lost more than 60% within a year and is currently trading at its low for the year.

    Even if SVB's difficulties do not directly affect banks in general, caution in the interbank business is increasing. Credit Suisse was already a problem child before last week. The future is likely to be challenging for the Swiss. Due to poor market conditions, some business, such as investment banking, could slip through Credit Suisse's fingers. The bank will soon be moving out of the "Zurich Main Tower" skyscrapers in the Oerlikon district - it is quite possible that this will not be the only downfall for Credit Suisse. Since the events surrounding SVB, problem banks will likely have a difficult time. It is likely that there will be consolidation in the industry in the coming weeks and that problem banks will be taken over by market companions.

    Aspermont: Corporate financing without risks

    While business with growth companies is becoming increasingly unattractive for banks and the turnaround in interest rates may have explosive effects in addition to positive consequences for the lending business, depending on the framework conditions of the individual banks, innovative fintech companies that do not take risks on their own books with their business could benefit. The global media company Aspermont sees itself as a specialist for content related to commodities, mining, energy and agricultural products. Almost every industrial company, as well as representatives from the production of raw materials, will probably have come into contact with publications from Aspermont at some time or another. Among others, the two traditional brands, Mining Journal and Mining Magazine, belong to the Company, which has consistently digitized its business with specialized media content in recent years.

    Virtually off the balance sheet, Aspermont launched a project last year that has what it takes to profit in the medium term as more and more banks pull back from financing growth companies. Aspermont and partners launched Blu Horseshoe, an intermediary platform for corporate financing that has already exceeded its goals in its first three months of operation. "We operate Blu Horseshoe as a majority shareholder together with renowned partners and see it as a test balloon of how well and effectively we can launch a new business using our existing resources. There are several potential additional Blu Horseshoes in our vision right now - for example, in e-learning," Alex Kent, managing director at Aspermont, said in an interview a few weeks ago. The main business for Aspermont continues to be in media content as well as being a specialized marketing agency.

    Prime address - but for how much longer? Credit Suisse building on Zurich's Paradeplatz Source: Credit Suisse

    If the air becomes increasingly thin for banks, riskier business areas and startup projects will likely suffer. A profiteer could be Aspermont, which already operates a financing platform for growth companies in Australia. Since Aspermont has long been internationally positioned with its global offices, other regions could become worthwhile targets. The stock is also considered extremely conservative: the valuation is low, and the main media content business has been growing steadily for 26 quarters - each year, Aspermont's media business is up 17%. Banks, on the other hand, will have to say goodbye to such growth figures for the time being - as long as they are not partners of Aspermont. The industry is under more pressure than ever since the euro crisis in 2011.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by Stefan Feulner on September 27th, 2023 | 08:30 CEST

    AI shares in focus: C3.ai, Norcom, Amazon - Upgrade at any cost

    • Software
    • AI
    • Technology

    The implementation of generative artificial intelligence on a large scale has the potential to significantly boost the German economy, according to a study by IW Consult, conducted on behalf of Google. In this context, the comprehensive integration of programs such as ChatGPT by at least half of domestic companies could increase economic output by around EUR 330 billion. This value corresponds to almost 10% of the German gross domestic product of the previous year. This is likely to herald a quantum leap for providers of intelligent software.

    Read

    Commented by André Will-Laudien on September 27th, 2023 | 08:05 CEST

    The high-tech gold rush on the Nasdaq is waning: BYD, Manuka Resources, and Infineon remain on the buy list

    • Mining
    • Vanadium
    • Electromobility
    • Technology
    • GreenTech

    For those investing in green or high-tech sectors, keeping an eye on the supply chains of raw materials is crucial. After all, in times of geopolitical upheaval, nothing seems more important to the industry than securing its foreign sources of critical resources. The EU and the US have already responded by adding several metals to the list of strategic elements. For the capital markets, too, the fight against global warming has become an issue that cannot be ignored. We focus on successful protagonists that can enhance any portfolio.

    Read